Study reveals cancer cell fuelling mechanism
Researchers have identified the process behind cancer cell energy production, providing a drug target for treatments to inhibit growth.
List view / Grid view
Researchers have identified the process behind cancer cell energy production, providing a drug target for treatments to inhibit growth.
Molecular Devices, LLC, today announced the launch of the next generation of its FLIPR® Penta High-Throughput Cellular Screening System.
New study shows that a subset of follicular helper T cells contributes to the hyposialylation of autoantibodies in rheumatoid arthritis.
Scientists have found a way to target and knock out a protein which is widely involved in pancreatic cancer cell growth, survival and invasion.
Researchers have discovered the mechanism behind a gateway into cells for glutamine, illuminating potential ways to prevent cancer cells from getting nutrients.
A study has used EEG to investigate the neuron networks that act abnormally in the condition, providing a significant step in the search for treatments.
Scientists report how editing a portion of stem cells with CRISPR-Cas9 is sufficient for long-term reactivation of therapeutic haemoglobin.
Researchers have newly found that protein CD24 acts as a defensive signal and is used by cancer cells to protect themselves.
A study has discovered that reducing expression of a key gene in neuroblastoma tumourigenesis is an important drug target for the condition.
New study sheds light on how the TP53 gene becomes mutated and how those mutations can help predict clinical outlooks for cancer.
Researchers have discovered a new combination therapy to treat drug-resistant acute lymphoblastic leukaemia, tested in pre-clinical trials.
Researchers have discovered a non-coding RNA which could be used as a biomarker and in new therapies for prostate cancer.
New discovery makes it possible to design new therapies to replace alpha-synuclein's function in people with Parkinson's disease.
Salk scientists discover a pair of enzymes that drive non-small-cell lung cancer by promoting inflammation which could inform the development of new therapies.
Newly developed HDO-antimiR could lead to new ways to treat diseases which are caused by malfunctioning miRNAs.